Journal article
Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)
Abstract
BACKGROUND/OBJECTIVE: Non-platinum-based chemotherapy is a potential alternative to platinum doublet therapy for advanced non-small cell lung cancer in selected patients. We determined the cost-effectiveness of gemcitabine/vinorelbine (GEMVIN), versus cisplatin/gemcitabine (PG) or cisplatin/vinorelbine (PV), from a government payer perspective.
METHODS: Results from a randomized trial of GEMVIN versus PG or PV demonstrated no significant …
Authors
Reaume MN; Leighl NB; Mittmann N; Coyle D; Hirsh V; Seymour L; Tu D; Shepherd FA; Graham B; Gridelli C
Journal
Lung Cancer, Vol. 82, No. 1, pp. 115–120
Publisher
Elsevier
Publication Date
October 2013
DOI
10.1016/j.lungcan.2013.07.012
ISSN
0169-5002
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCisplatinClinical Trials, Phase III as TopicCost-Benefit AnalysisDeoxycytidineHumansLung NeoplasmsNeoplasm StagingRandomized Controlled Trials as TopicRetrospective StudiesSurvival AnalysisTreatment OutcomeVinblastineVinorelbineGemcitabine